MCID: CPL005
MIFTS: 36

Capillary Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Capillary Disease

MalaCards integrated aliases for Capillary Disease:

Name: Capillary Disease 12 14
Disease of Capillaries 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1271
ICD10 33 I78 I78.9
ICD9CM 35 448
UMLS 69 C0155765

Summaries for Capillary Disease

Disease Ontology : 12 A vascular disease that is located in the capillaries.

MalaCards based summary : Capillary Disease, also known as disease of capillaries, is related to cataract and cerebral sarcoidosis. An important gene associated with Capillary Disease is IL2 (Interleukin 2), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Calcineurin-regulated NFAT-dependent transcription in lymphocytes. The drugs Bosentan and rituximab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and testes, and related phenotypes are homeostasis/metabolism and mortality/aging

Wikipedia : 72 A capillary (/ˈkæpɪlɛriz/ in US; /kəˈpɪləriz/ in UK) is a hollow tube 5 to 10 micrometres (µm) in... more...

Related Diseases for Capillary Disease

Diseases related to Capillary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 32)
id Related Disease Score Top Affiliating Genes
1 cataract 10.4 ALB CSF2
2 cerebral sarcoidosis 10.4 ALB IL2
3 lymphocytic gastritis 10.4 ALB CSF2
4 exudative vitreoretinopathy 2, x-linked 10.4 ALB CSF2
5 bardet-biedl syndrome 17 10.4 ALB SERPING1
6 gastric ulcer 10.4 ALB IL2
7 renal tubular acidosis 10.4 CSF2 IL2
8 zika virus congenital syndrome 10.3 CSF2 IL2
9 chronic endophthalmitis 10.3 ALB CSF2
10 opportunistic bacterial infectious disease 10.3 ALB IL2
11 dyskeratosis congenita 10.3 ALB IL36RN
12 mucocutaneous leishmaniasis 10.2 ALB IL2
13 vascular disease 10.2 ALB ATP4A
14 lymphoma 10.2 ALB IL2
15 polysyndactyly with cardiac malformation 10.2 ALB ATP4A
16 cryptogenic organizing pneumonia 10.1 ALB ATP4A
17 labyrinthine bilateral reactive loss 10.1 ALB CSF2 IL2
18 angelucci's syndrome 10.1 ALB ATP4A
19 benign mammary dysplasia 10.1 ALB CSF2 IL2
20 acral lentiginous melanoma 10.1 ALB CSF2 IL2
21 uterus interstitial leiomyoma 10.1 ALB IL2
22 hyperpigmentation of eyelid 10.1 ALB IL2
23 lacrimal system cancer 10.1 ALB CSF2 IL2
24 pediatric infratentorial ependymoblastoma 10.1 ALB ATP4A
25 submucous uterine fibroid 10.0 ALB ANGPT2
26 hereditary hemorrhagic telangiectasia 9.9
27 vernal conjunctivitis 9.8 ALB ANGPT2
28 acute chest syndrome 9.8 ALB CSF2
29 systemic capillary leak syndrome 9.7
30 citrullinemia, adult-onset type ii 9.5 ALB ANGPT2
31 malaria 9.3 ALB ANGPT2 CSF2 IL2
32 chronic gonococcal salpingitis 6.8 ALB ANGPT2 ATP4A CSF2 ECI1 IL2

Graphical network of the top 20 diseases related to Capillary Disease:



Diseases related to Capillary Disease

Symptoms & Phenotypes for Capillary Disease

MGI Mouse Phenotypes related to Capillary Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.5 ALB ANGPT2 ATP4A CSF2 ECI1 IL2
2 mortality/aging MP:0010768 9.17 STAMBP ALB ANGPT2 ATP4A CSF2 IL2

Drugs & Therapeutics for Capillary Disease

Drugs for Capillary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 419)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 2 147536-97-8 104865
2
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
4
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-24-8 5755
7
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613 2171
8
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
9
Dexlansoprazole Approved Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
11
Insulin Lispro Approved Phase 4 133107-64-9
12
Zinc Approved Phase 4 7440-66-6 32051 23994
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Metformin Approved Phase 4,Phase 1 657-24-9 14219 4091
16
Insulin Glargine Approved Phase 4 160337-95-1
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
20 Racepinephrine Approved Phase 4
21
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
22
Hydroxychloroquine Approved Phase 4 118-42-3 3652
23
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2068-78-2, 57-22-7 5978
24
Bisoprolol Approved Phase 4 66722-44-9 2405
25
Candesartan Approved Phase 4 139481-59-7 2541
26
Captopril Approved Phase 4,Phase 1,Phase 2 62571-86-2 44093
27
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
28
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56329 56330
29
Enalapril Approved, Vet_approved Phase 4,Phase 1,Phase 2 75847-73-3 5362032 40466924
30
Enalaprilat Approved Phase 4,Phase 1,Phase 2 76420-72-9 6917719
31
Eprosartan Approved Phase 4 133040-01-4 5281037
32
Fosinopril Approved Phase 4 98048-97-6 55891
33
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
34
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
35
Losartan Approved Phase 4 114798-26-4 3961
36
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
39
Ramipril Approved Phase 4 87333-19-5 5362129
40
Spirapril Approved Phase 4 83647-97-6 5311447
41
Trandolapril Approved Phase 4 87679-37-6 5484727
42
Artemether Approved Phase 4 71963-77-4 119380 68911
43
Lumefantrine Approved Phase 4 82186-77-4 6437380
44
Eplerenone Approved Phase 4 107724-20-9 150310 443872
45
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
46
Bevacizumab Approved, Investigational Phase 4 216974-75-3
47
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
49
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
50
Caffeic acid Experimental Phase 4,Phase 3 331-39-5 1549111

Interventional clinical trials:

(show top 50) (show all 542)

id Name Status NCT ID Phase Drugs
1 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Unknown status NCT02480335 Phase 4 bosentan
2 Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study Completed NCT00460213 Phase 4 Valsartan 80mg daily;Valsartan 160mg daily
3 Metformin in Chronic Obstructive Pulmonary Disease Completed NCT01247870 Phase 4 Metformin;Placebo
4 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
5 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
6 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
7 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
8 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
9 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
10 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
11 Glargine Versus NPH in Patients With Chronic Kidney Disease Completed NCT02451917 Phase 4 Glargine;NPH insulin
12 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
13 Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children Completed NCT01632046 Phase 4 lactate and bicarbonate buffered dialysis solutions
14 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
15 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
16 Estimated Echocardiographic Pulmonary Capillary Wedge Pressure in Heart Failure Completed NCT01738659 Phase 4
17 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Recruiting NCT02249897 Phase 4 CHOLESTYRAMINE
18 NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients Recruiting NCT02817360 Phase 4 RAS-antagonist and beta-blocker up-to maximal dosages
19 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
20 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
21 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Recruiting NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
22 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Recruiting NCT02574403 Phase 4 eculizumab
23 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease Recruiting NCT02752191 Phase 4 ferumoxytol;gadofosveset
24 Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot Recruiting NCT02742285 Phase 4 Artemether + lumefantrine
25 Comparison of High Flow Oxygenation Therapy and CPAP in Children With Bronchiolitis. Recruiting NCT02618213 Phase 4
26 Aldosterone Antagonism and Microvascular Function Recruiting NCT01887119 Phase 4 Eplerenone
27 Ramipril Treatment of Claudication Recruiting NCT02842424 Phase 4 Ramipril
28 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS Recruiting NCT02276066 Phase 4 Iohexol
29 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes Recruiting NCT02682563 Phase 4 Dapagliflozin 10mg QD;Gliclazide 30mg QD
30 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Enrolling by invitation NCT02614898 Phase 4
31 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Not yet recruiting NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
32 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
33 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Not yet recruiting NCT03246152 Phase 4 Bevacizumab
34 Use of Nesiritide in the Management of Acute Diastolic Heart Failure Terminated NCT00083772 Phase 4 Nesiritide
35 Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels Terminated NCT00559286 Phase 4 Telmisartan
36 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
37 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
38 Effects of Canagliflozin on Intravascular Volume and Hemodynamics Withdrawn NCT03190798 Phase 4 Canagliflozin 300mg;Placebo
39 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
40 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
41 Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults Unknown status NCT00581087 Phase 3 DHEA treatment;Placebo
42 Randomized Trial of Erythropoietin During Cerebral Malaria Unknown status NCT00697164 Phase 2, Phase 3 Placebo;Erythropoietin
43 Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image Unknown status NCT00172562 Phase 3
44 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
45 Effects of Saxagliptin on Endothelial Function Completed NCT01319357 Phase 3 Saxagliptin;Placebo
46 Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease Completed NCT00560261 Phase 3
47 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
48 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
49 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
50 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)

Search NIH Clinical Center for Capillary Disease

Genetic Tests for Capillary Disease

Anatomical Context for Capillary Disease

MalaCards organs/tissues related to Capillary Disease:

39
Endothelial, Heart, Testes, Bone, Bone Marrow, Lung, Kidney

Publications for Capillary Disease

Articles related to Capillary Disease:

id Title Authors Year
1
Growth hormone, sorbitol, and diabetic capillary disease. ( 4102056 )
1971
2
Growth hormone, sorbitol, and diabetic capillary disease. ( 4100908 )
1971

Variations for Capillary Disease

Expression for Capillary Disease

Search GEO for disease gene expression data for Capillary Disease.

Pathways for Capillary Disease

GO Terms for Capillary Disease

Cellular components related to Capillary Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 ALB ANGPT2 CSF2 IL2 IL36RN SERPING1
2 extracellular space GO:0005615 9.17 ALB ANGPT2 ATP4A CSF2 IL2 IL36RN
3 platelet alpha granule lumen GO:0031093 9.16 ALB SERPING1

Biological processes related to Capillary Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.62 CSF2 IL2

Molecular functions related to Capillary Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 CSF2 IL2 IL36RN

Sources for Capillary Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....